Chimin Health Management Co., Ltd. Class A

Chimin Health Management Co., Ltd. Class A

SSSE:603222
6.89
CNY
+0.02
(+0.29%)
-0.50EPS
4.24BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.67
1.45
1.05
1.02
1.38
1.55
1.75
1.96
2.31
1.7
1.64
1.43
1.31
1.24
Basic EPS, GAAP
0.24
0.17
0.12
0.09
0.12
0.07
0.16
0.01
0.31
0.07
-0.12
-0.11
-0.47
-0.48
Free Cash Flow per Basic Share
0.23
0.12
-0.04
-0.06
-0.6
-0.3
0.04
- -
-0.02
0.02
-0.02
-0.09
-0.11
- -
Dividend per Share
0.11
0.12
0.06
0.02
0.06
0.1
0.13
0.13
0.08
0.12
0.06
0.03
0.04
0.04
Book Value per Share
1.45
1.31
1.61
1.68
1.77
1.81
1.95
1.93
2.6
3.58
2.93
2.82
2.32
2.01
Tangible Book Value per Share
1.18
1.04
1.41
1.31
0.93
0.85
1.22
1.24
2
3
2.48
2.37
1.93
1.62
Basic Weighted Avg Shares
335
336
426
440
436
449
440
448
476
492
546
543
523
517
Sales/Revenue/Turnover
559
488
449
450
603
698
771
878
1,098
837
895
776
686
639
Operating Margin (%)
17.93
14.98
12.86
9.27
15.01
10.13
13.4
14.09
20.03
12.49
6.24
-4.08
-13.75
-18.69
Depreciation Expense
28
29
29
32
37
50
66
71
86
84
103
117
114
- -
Net Income, GAAP
81
58
52
41
53
32
69
6
148
34
-65
-60
-246
-251
Effective Tax Rate (%)
14.56
15.12
14.55
16.84
21.28
18.53
20.18
226
20.88
39.17
- -
- -
- -
- -
Profit Margin (%)
14.52
11.79
11.54
9.08
8.77
4.59
8.97
0.73
13.43
4.12
-7.32
-7.7
-35.8
-39.21
Working Capital
213
175
415
397
-14
-88
40
-170
90
462
268
229
-49
-227
LT Debt
- -
- -
- -
1
139
368
334
192
260
330
335
323
304
262
Total Equity
488
442
751
809
928
1,047
1,073
1,046
1,375
1,774
1,660
1,568
1,306
1,134
Return on Invested Capital (%)
12.9
9.66
8.03
5.04
5.62
2.97
4.08
-2.17
6.78
1.27
- -
- -
- -
- -
Return on Capital (%)
14.35
10.39
7.92
5.4
5.74
2.53
5.12
-1.67
9.54
2.71
- -
- -
- -
- -
Return on Common Equity (%)
17.65
12.39
8.9
5.56
6.85
4
8.23
0.74
14.03
2.34
-3.99
-3.91
-18.19
-20.22

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
483
509
526
LT Borrowings
234
224
209
LT Finance Leases
57
53
53
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
525
525
525
Market Capitalization
4,694
4,437
4,237

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
559
673
507
Cash, Cash Equivalents & STI
282
400
231
Accounts Receivable, Net
111
110
121
Inventories
104
105
96
Total Current Liabilities
712
717
733
Payables & Accruals
- -
- -
- -
ST Debt
483
509
526
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.7%
6.35%
-16.75%
Free Cash Flow
112.91%
86.19%
15.38%
Net Income, GAAP
213.58%
428.36%
311.28%
Sales/Revenue/Turnover
5.77%
-3.33%
-11.57%
Total Cash Common Dividend
13.51%
-10.52%
18.34%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
234
232
217
93
776
2025
181
185
- -
141
686
2026
163
175
160
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.02
0.01
-0.17
-0.11
2025
-0.03
-0.07
- -
-0.32
-0.47
2026
-0.05
-0.05
-0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.03
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Yunfei Tian
Full Time Employees
1,890
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 888, Beiyuan Road Taizhou ZH China 318020
IPO Date
Feb 9, 2015
Website
chimin.cn
Business
Chimin Health Management Co., Ltd. (603222.SS) researches, develops, produces and sells pharmaceuticals, medical devices and comprehensive medical services in China and internationally. The company offers core pharmaceutical products including nearly 40 varieties of large-volume infusions such as balanced, nutritional, therapeutic infusions and external irrigation agents in non-PVC soft bags and disposable polypropylene plastic bottles; its flagship double-pipe double-valve non-PVC soft bag infusion holds over 30% market share in East and South China and exports to more than 30 countries in Southeast Asia, Africa and South America. Medical devices encompass safety self-destruct syringes, safety injection needles, sterile syringes, irrigators, insulin syringes, infusion sets, precision filter infusion sets, hemodialysis concentrates and other injection puncture products; in vitro diagnostic reagents cover clinical chemistry, immunological, blood testing, rapid and enzyme-linked diagnostics, with laboratory instruments and kits like FOB fecal occult blood and Helicobacter pylori detection; comprehensive medical services operate 18 hemodialysis centers and three general hospitals including Boao International Hospital. Founded in 1996 and headquartered in Huangyan District, Taizhou City, Zhejiang Province, China, Chimin maintains three production bases in Zhejiang, Shanghai and Spain, plus nine subsidiaries such as Shanghai Jumin Biotechnology Co., Ltd., Taizhou Jurui Plastic Technology Co., Ltd., Spain Linear Chemical Co., Ltd. and Hainan Jumin Boao International Hospital Co., Ltd.; it pursues a "comprehensive health strategy" of one main business (medical services) and two wings (pharmaceuticals and devices). Recent developments include acceptance on September 26, 2025, by China's National Medical Products Administration of a clinical trial application for DB006 oncolytic adenovirus injection by subsidiary Boao International Hospital to treat advanced malignant solid tumors; a May 2025 strategic cooperation framework agreement between Boao International Hospital and Dabo Biotech for new drug development and clinical transformation in Hainan's Lecheng Pilot Zone; cumulative repurchase of 2.0055 million shares as of November 30, 2025, under a CNY 200 million program initiated in March 2025; and ongoing partnerships with U.S. firm RTI, United Nations Red Cross, Oda Hospital for cell therapy technologies, Italian University of Turin and domestic research institutions.